Search research articles
Contact Us
Filters
Showing results (161-170 of 190) with videos related to
Page
of 19
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 14, 2018
Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report
Josephine Mauskopf, Baudouin Standaert, Mark P Connolly, et al.
Current Medical Research and Opinion
|
November 17, 2011
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
Richard M Bergenstal, Louis P Garrison, Lesley-Ann Miller, et al.
Pharmacoepidemiology and Drug Safety
|
June 4, 2014
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies
Anita J Chawla, Daniel S Mytelka, Stephan D McBride, et al.
The Journal of Infectious Diseases
|
June 14, 2011
Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program
Joseph B Babigumira, Ann Levin, Colleen Burgess, et al.
Neurology and Therapy
|
September 18, 2024
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States
Malaz Boustani, Erin G Doty, Louis P Garrison, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 27, 2021
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States
Courtney D Thornburg, Kelly Adamski, Keziah Cook, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 5, 2021
Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis
Louis P Garrison, Patricia Schepman, Andrew G Bushmakin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 31, 2009
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I
Joel W Hay, Jim Smeeding, Norman V Carroll, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn, Louis P Garrison, Anja K Pownell, et al.
Current Medical Research and Opinion
|
January 12, 2011
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
Richard M Bergenstal, Louis P Garrison, Matthew Wintle, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 190) with videos related to
Sort By:
Page
of 19
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 14, 2018
Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report
Josephine Mauskopf, Baudouin Standaert, Mark P Connolly, et al.
Current Medical Research and Opinion
|
November 17, 2011
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
Richard M Bergenstal, Louis P Garrison, Lesley-Ann Miller, et al.
Pharmacoepidemiology and Drug Safety
|
June 4, 2014
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies
Anita J Chawla, Daniel S Mytelka, Stephan D McBride, et al.
The Journal of Infectious Diseases
|
June 14, 2011
Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program
Joseph B Babigumira, Ann Levin, Colleen Burgess, et al.
Neurology and Therapy
|
September 18, 2024
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States
Malaz Boustani, Erin G Doty, Louis P Garrison, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 27, 2021
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States
Courtney D Thornburg, Kelly Adamski, Keziah Cook, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 5, 2021
Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis
Louis P Garrison, Patricia Schepman, Andrew G Bushmakin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 31, 2009
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I
Joel W Hay, Jim Smeeding, Norman V Carroll, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn, Louis P Garrison, Anja K Pownell, et al.
Current Medical Research and Opinion
|
January 12, 2011
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
Richard M Bergenstal, Louis P Garrison, Matthew Wintle, et al.
Page
of 19